Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
SSH's Cash to Debt is ranked higher than
96% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. SSH: No Debt )
SSH' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.90
SSH's Equity to Asset is ranked higher than
96% of the 470 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. SSH: 0.90 )
SSH' s 10-Year Equity to Asset Range
Min: 0.1   Max: 0.98
Current: 0.9

0.1
0.98
Interest Coverage No Debt
SSH's Interest Coverage is ranked higher than
76% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 436.41 vs. SSH: No Debt )
SSH' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 8.96
M-Score: -0.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -8741.36
SSH's Operating margin (%) is ranked lower than
58% of the 486 Companies
in the Global Medical Devices industry.

( Industry Median: 4.88 vs. SSH: -8741.36 )
SSH' s 10-Year Operating margin (%) Range
Min: -38764.41   Max: -358.24
Current: -8741.36

-38764.41
-358.24
Net-margin (%) -8673.56
SSH's Net-margin (%) is ranked lower than
58% of the 486 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. SSH: -8673.56 )
SSH' s 10-Year Net-margin (%) Range
Min: -36877.97   Max: -358.24
Current: -8673.56

-36877.97
-358.24
ROE (%) -63.10
SSH's ROE (%) is ranked higher than
50% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. SSH: -63.10 )
SSH' s 10-Year ROE (%) Range
Min: -238.68   Max: -63.22
Current: -63.1

-238.68
-63.22
ROA (%) -58.78
SSH's ROA (%) is ranked higher than
51% of the 513 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. SSH: -58.78 )
SSH' s 10-Year ROA (%) Range
Min: -216.94   Max: -58.42
Current: -58.78

-216.94
-58.42
ROC (Joel Greenblatt) (%) -4317.98
SSH's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 5.54 vs. SSH: -4317.98 )
SSH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4851.22   Max: -774.91
Current: -4317.98

-4851.22
-774.91
EBITDA Growth (3Y)(%) 432.50
SSH's EBITDA Growth (3Y)(%) is ranked higher than
100% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. SSH: 432.50 )
SSH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 462.5
Current: 432.5

0
462.5
EPS Growth (3Y)(%) 322.70
SSH's EPS Growth (3Y)(%) is ranked higher than
99% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. SSH: 322.70 )
SSH' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 455
Current: 322.7

0
455
» SSH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SSH Guru Trades in

SSH Guru Trades in

Q3 2013

SSH Guru Trades in Q3 2013

Jim Simons 17,000 sh (New)
» More
Q4 2013

SSH Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SSH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.70
SSH's P/B is ranked higher than
75% of the 576 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. SSH: 2.70 )
SSH' s 10-Year P/B Range
Min: 2.1   Max: 3.32
Current: 2.7

2.1
3.32
P/S 257.78
SSH's P/S is ranked lower than
77% of the 576 Companies
in the Global Medical Devices industry.

( Industry Median: 4.21 vs. SSH: 257.78 )
SSH' s 10-Year P/S Range
Min: 257.7   Max: 575
Current: 257.78

257.7
575
Current Ratio 10.04
SSH's Current Ratio is ranked higher than
95% of the 505 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. SSH: 10.04 )
SSH' s 10-Year Current Ratio Range
Min: 4.37   Max: 40.76
Current: 10.04

4.37
40.76
Quick Ratio 10.04
SSH's Quick Ratio is ranked higher than
97% of the 505 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. SSH: 10.04 )
SSH' s 10-Year Quick Ratio Range
Min: 4.37   Max: 40.76
Current: 10.04

4.37
40.76
Days Sales Outstanding 73.00
SSH's Days Sales Outstanding is ranked higher than
76% of the 576 Companies
in the Global Medical Devices industry.

( Industry Median: 83.34 vs. SSH: 73.00 )
SSH' s 10-Year Days Sales Outstanding Range
Min: 6.99   Max: 803
Current: 73

6.99
803

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.70
SSH's Price/Net Cash is ranked higher than
99% of the 576 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SSH: 2.70 )
SSH' s 10-Year Price/Net Cash Range
Min: 2.55   Max: 4.65
Current: 2.7

2.55
4.65
Price/Net Current Asset Value 2.70
SSH's Price/Net Current Asset Value is ranked higher than
97% of the 576 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SSH: 2.70 )
SSH' s 10-Year Price/Net Current Asset Value Range
Min: 2.52   Max: 4.54
Current: 2.7

2.52
4.54
Price/Tangible Book 2.60
SSH's Price/Tangible Book is ranked higher than
85% of the 576 Companies
in the Global Medical Devices industry.

( Industry Median: 8.40 vs. SSH: 2.60 )
SSH' s 10-Year Price/Tangible Book Range
Min: 2.13   Max: 32.6
Current: 2.6

2.13
32.6
Price/Median PS Value 1.00
SSH's Price/Median PS Value is ranked higher than
81% of the 576 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. SSH: 1.00 )
SSH' s 10-Year Price/Median PS Value Range
Min: 0.99   Max: 0.99
Current: 1

Earnings Yield (Greenblatt) -56.70
SSH's Earnings Yield (Greenblatt) is ranked lower than
66% of the 492 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. SSH: -56.70 )
SSH' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1413.4   Max: 0
Current: -56.7

-1413.4
0

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:SHC.Australia, 22S.Germany,
Sunshine Heart, Inc. was incorporated in Delaware on August 22, 2002. The company is an early-stage medical device company engaged in developing, manufacturing and commercializing its C-Pulse Heart Assist System for treatment of Class III and ambulatory Class IV heart failure. Its C-Pulse Heart Assist System utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. It is in the process of obtaining regulatory approvals necessary to sell its product. Combined, these potential benefits may help reverse the heart failure process or maintain the patient's current condition, thereby potentially preventing the need for later-stage heart failure devices, such as LVADs, artificial hearts or transplants. Its competitors include: AbioMed, Inc., Berlin Heart GmbH, CardioKinetix, Inc., CircuLite, Inc. & HeartWare International Inc. Its business is subject to extensive federal and state government regulation.
» More Articles for SSH

Headlines

Articles On GuruFocus.com

More From Other Websites
Sunshine Heart Provides Update on U.S. Pivotal Study of C-Pulse(R) Heart Assist System Apr 18 2015
SUNSHINE HEART, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 17 2015
Excitement Among Proof-of-Concept Drug Companies Could Spill Over Into This Lesser-Known Name Apr 17 2015
Sunshine Heart Provides Update on U.S. Pivotal Study of C-Pulse(R) Heart Assist System Apr 16 2015
SUNSHINE HEART, INC. Financials Mar 26 2015
SUNSHINE HEART, INC. Files SEC form 10-K, Annual Report Mar 20 2015
Sunshine Heart, Inc. Secures Up to $10 Million in Growth Capital From Silicon Valley Bank Mar 19 2015
Sunshine Heart Provides Update on U.S. Pivotal Study of C-Pulse(R) Heart Assist System Mar 19 2015
Sunshine Heart Receives FDA Approval for Interim Analysis of U.S. Pivotal Trial of C-Pulse(R) Heart... Mar 19 2015
Sunshine Heart Announces Fourth Quarter and Twelve Months 2014 Financial Results and Provides... Mar 19 2015
Q4 2014 Sunshine Heart Inc Earnings Release - Time Not Supplied Mar 17 2015
SUNSHINE HEART, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 17 2015
Sunshine Heart reports 4Q loss Mar 17 2015
Sunshine Heart reports 4Q loss Mar 17 2015
Sunshine Heart Announces Fourth Quarter and Twelve Months 2014 Financial Results and Provides... Mar 17 2015
Sunshine Heart to Release Fourth Quarter and Year-End 2014 Results on March 17, 2015 Mar 10 2015
Sunshine Heart (SSH) Stock Drops Today After Suspending Study Enrollment Mar 06 2015
SUNSHINE HEART, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Mar 06 2015
Sunshine Heart Provides Update on U.S. Pivotal Study of C-Pulse(R) Heart Assist System Mar 06 2015
Sunshine Heart Could Be Worth 10X What Thoratec Tried To Pay For Heartware in 2010 Mar 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK